We are thrilled to announce the addition of Dr. Deepak “Dee” Khuntia, M.D., FASTRO, to the esteemed Board of Directors at TAE Life Sciences. Dr. Khuntia's vast expertise in radiation oncology and his significant contributions to advancing cancer treatment technologies significantly reinforce our company’s dedication to pioneering advancements in the field.
Dr. Khuntia boasts an illustrious career spanning several decades, during which he has played a pivotal role in shaping the modern landscape of radiation oncology. His role as the Senior Vice President of Medical Affairs and Chief Medical Officer at Varian, a Siemens Healthineers Company, has seen him spearhead transformative initiatives in cancer care. Notably, his contributions have been instrumental in enhancing treatment strategies for brain tumors, head and neck cancer, and lung cancer—areas closely aligned with the types of cancers TAE Life Sciences aims to target with Boron Neutron Capture Therapy (BNCT).
The addition of Dr. Khuntia to our board further solidifies TAE Life Sciences’ position as a leader in the development of innovative cancer treatment solutions. It underscores our unwavering commitment to providing hope and healing to patients worldwide through the precise cancer-targeting capabilities of BNCT.
Continuing our tradition of attracting top-tier talent, Dr. Khuntia's appointment exemplifies our dedication to revolutionizing cancer treatment. It underscores our commitment to advancing BNCT and reaffirms our position as a pioneer in precision radiation oncology. Through collaborative efforts with esteemed professionals like Dr. Khuntia, TAE Life Sciences is poised to continue driving advancements in
cancer care, offering new hope to patients globally.
